A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine

Кибитов, А.О.; Krupitsky, Evgeny; Blokhina, Elena; Verbitskaya, E.; Brodyansky, V. M.; Алексеева, Н. П.; Bushara, Natalia; Yaroslavtseva, T. V.; Palatkin, V.; Masalov, D.; Burakov, A.M.; Romanova, Tatyana N.; Sulimov, G Yu; Grinenko, A.; Kosten, Thomas R.; Nielsen, David A.; Zvartau, Edwin

doi:10.17116/jnevro201611611236-48

Cited by 2 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A pharmacogenetic component of the collaborative double-blind, double-dummy, placebo-controlled randomized clinical trial of implantable naltrexone vs. oral naltrexone and placebo for opioid dependence (Molecular Genetics Laboratory of the SNMRCPA, Moscow; Department of Addictions, BNMRCPN; the Laboratory of Clinical Psychopharmacology of Addictions, First Saint Petersburg Pavlov State Medical University; and Baylor College of Medicine, TX, USA) showed the joint effect of opioid receptor genes and genes of the dopaminergic system on treatment outcomes [76]. In another study, this collaborative group showed the additive effect of opioid receptor genes and dopaminergic system genes on outcomes of treatment of opioid dependence with oral naltrexone and guanfacine [77].…”

Section: The Modern Landscape Of Psychiatric Genetics In the Russian mentioning

confidence: 99%

Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium

et al. 2019

View full text Add to dashboard Cite

We provide an overview of the recent achievements in psychiatric genetics research in the Russian Federation and present genotype-phenotype, population, epigenetic, cytogenetic, functional, ENIGMA, and pharmacogenetic studies, with an emphasis on genome-wide association studies. The genetic backgrounds of mental illnesses in the polyethnic and multicultural population of the Russian Federation are still understudied. Furthermore, genetic, genomic, and pharmacogenetic data from the Russian Federation are not adequately represented in the international scientific literature, are currently not available for meta-analyses and have never been compared with data from other populations. Most of these problems cannot be solved by individual centers working in isolation but warrant a truly collaborative effort that brings together all the major psychiatric genetic research centers in the Russian Federation in a national consortium. For this reason, we have established the Russian National Consortium for Psychiatric Genetics (RNCPG) with the aim to strengthen the power and rigor of psychiatric genetics research in the Russian Federation and enhance the international compatibility of this research.The consortium is set up as an open organization that will facilitate collaborations on complex biomedical research projects in human mental health in the Russian Federation and abroad. These projects will include genotyping, sequencing, transcriptome and epigenome analysis, metabolomics, and a wide array of other state-of-the-art analyses. Here, we discuss the challenges we face and the approaches we will take to unlock the huge potential that the Russian Federation holds for the worldwide psychiatric genetics community.

show abstract

Section: The Modern Landscape Of Psychiatric Genetics In the Russian mentioning

confidence: 99%

Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium

et al. 2019

View full text Add to dashboard Cite

show abstract

BDNF, DRD4, and HTR2A Gene Allele Frequency Distribution and Association with Mental Illnesses in the European Part of Russia

Morozova,

Ushakova,

Pavlova

et al. 2024

Genes

View full text Add to dashboard Cite

The prevalence of mental disorders and how they are diagnosed represent some of the major problems in psychiatry. Modern genetic tools offer the potential to reduce the complications concerning diagnosis. However, the vast genetic diversity in the world population requires a closer investigation of any selected populations. In the current research, four polymorphisms, namely rs6265 in BDNF, rs10835210 in BDNF, rs6313 in HTR2A, and rs1800955 in DRD4, were analyzed in a case–control study of 2393 individuals (1639 patients with mental disorders (F20-F29, F30-F48) and 754 controls) from the European part of Russia using the TaqMan SNP genotyping method. Significant associations between rs6265 BDNF and rs1800955 DRD4 and mental impairments were detected when comparing the general group of patients with mental disorders (without separation into diagnoses) to the control group. Associations of rs6265 in BDNF, rs1800955 in DRD4, and rs6313 in HTR2A with schizophrenia in patients from the schizophrenia group separately compared to the control group were also found. The obtained results can extend the concept of a genetic basis for mental disorders in the Russian population and provide a basis for the future improvement in psychiatric diagnostics.

show abstract

A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine

Cited by 2 publications

References 39 publications

Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium

Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium

BDNF, DRD4, and HTR2A Gene Allele Frequency Distribution and Association with Mental Illnesses in the European Part of Russia

Contact Info

Product

Resources

About